Catalyst Pharmaceutical Partners, Inc.Coral Gables, FL United States
Company Description
Catalyst Pharmaceutical Partners may help certain addicts kick the habit. The development-stage company's lead candidate, CPP-109 (based on the chemical compound vigabatrin), is in clinical studies for the treatment of cocaine and methamphetamine addiction. The drug is designed to be readily absorbed into the central nervous system, preventing the perception of pleasure that results from dramatic increases in dopamine caused by cocaine and meth use. Contract manufacturer Pharmaceutics International is supplying CPP-109 for use in upcoming clinical trials and may also be contracted for future commercial supplies should the drug become approved in the US.
| 355 Alhambra Circle, Ste. 1370 | Phone: 305-529-2522 | http://www.catalystpharma.com |
| Coral Gables, FL 33134 | Fax: 305-529-0933 | 
Map This Company |
| United States |
Try a Full Premium Subscription
Access over 85 million companies
Call (866) 443-3939 or
Prepare for your Sales call
Try a Small Business Subscription
Starting $89 per month
Catalyst Pharmaceutical Partners, Inc. Rankings
Executives
| 7 executives listed for Catalyst Pharmaceutical Partners, Inc.'s Coral Gables, FL location. | ||
| Chairman, President, and CEO | Patrick McEnany | |
|---|---|---|
| COO and Chief Scientific Officer | Steven Miller | |
| VP, CFO, and Treasurer | Jack Weinstein | |
Financials
| Company Type | Public - NASDAQ: CPRX Single Location |
|---|---|
| Fiscal Year-End | December |
| 2011 Employees | 6 |
DNBiLeverage D&B's credit assessment tools to positively impact
your business. Get the scoop on Catalyst Pharmaceutical Partners, Inc. now.
- Reduce risk.
- Drive greater profitability.
- Increase cash flow.
